&lt;p&gt;Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma&lt;/p&gt;

Zhou, Liya; Lin, Jie; Wu, Gang; Chen, Jiawei; Huang, Xiaopeng; Zhang, Shuai

doi:10.2147/dddt.s244102

Cited by 16 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ORR ranged from 31.37%-36.4%. Median OS were 16-22 months and median PFS were 5-9 months [25][26][27]. Consistently, in our study, the median OS of patients with nasopharyngeal carcinoma treated with apatinib was 20.87 months (95% CI: 0-48.33), and median PFS was 11.53 months.…”

Section: Discussionsupporting

confidence: 85%

Apatinib in recurrent or metastatic head and neck cancer patients

Jia

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Apatinib is a small tyrosine kinase inhibitor targeting the vascular endogenous growth receptor 2 (VEGFR-2) that shows potent anti-tumor activities in various advanced cancers via the inhibition of neo-angiogenesis. The effect of apatinib in recurrent or metastatic head and neck cancers is not fully demonstrated. Methods Patients with recurrent or metastatic head and neck cancers consecutively treated in our institute by apatinib from January 2015 to June 2022 were enrolled. Daily 250 mg or 500 mg apatinib was given with or without chemotherapy according to patients' tolerance. Disease response, treatment-related side effects and patient survival were analyzed. Kaplan-Meier analysis was used to estimate patients' overall survival. The R software (version 4.1.3) were used for statistical analysis. Results A total of 85 patients (median [range] age, 53 [23-79] years; 68 male [80.0%]) were included for analysis. The median follow-up time was 30.4 (95% CI: 23.95- 40.70) months. By the end of the last follow-up, 43 (50.6%) patients died of disease progression. The median OS was 29.6 (95% CI: 12.39- 46.75) months, and the median PFS was 10.4 (95% CI: 6.11- 14.63) months. The ORR was 21.2%, and the DCR was 70.6%. The side effects were manageable and no treatment-associated death occurred. Multivariate analysis showed that OS was significantly associated with cancer pathology (squamous cell carcinoma vs. adenoid cystic carcinoma, HR=6.42, 95%CI:1.50-27.39, p = 0.0121; other types (adenocarcinoma, sarcoma, melanoma) vs. adenoid cystic carcinoma, HR=3.58, 95%CI:1.02-12.52, p = 0.0459). Conclusion Apatinib showed promising anti-tumor activities in recurrent or metastatic head and neck cancers. The side effects were manageable. The effect of apatinib in recurrent or metastatic head and neck cancers warrants further verifications in larger-scale randomized studies.

show abstract

Section: Discussionsupporting

confidence: 85%

Apatinib in recurrent or metastatic head and neck cancer patients

Jia

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Low-dose apatinib has been applied in the treatment of several cancers with good efficacy and tolerable adverse events, such as advanced nonsmall cell lung cancer, pulmonary, hepatic metastasis of nasopharyngeal carcinoma, etc. (13,29). In terms of GC/ GEJAC, only two single-arm observational studies have revealed that low-dose apatinib is effective and tolerated for advanced GC patients (14,30).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study

Yan¹,

Li²,

Wu³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Previous studies of the second-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJAC) had reported that apatinib combined with chemotherapy improved the treatment outcomes. However, the benefits were sometimes limited due to the tolerance of continuous dose regimen. This randomized controlled study aimed to investigate the efficacy and safety of intermittent or continuous dose apatinib plus docetaxel as a second-line therapy in patients with advanced GC/GEJAC. Methods: Advanced GC/GEJAC patients who failed first-line chemotherapy were recruited (enrollment time: from September 15, 2017 to July 21, 2019), and randomly assigned to either the intermittent dose group (IG group) or the continuous dose group (CG group) (1:1 ratio) using the block randomization method. In the IG group, patients received apatinib 500 mg/d for 5 consecutive days then held for 2 days plus docetaxel 60 mg/m 2 q3w, in a 3-week cycle. In the CG group, patients received apatinib 500 mg daily plus docetaxel 60 mg/m 2 q3w, in a 3-week cycle. The progression free survival (PFS) was evaluated every two cycles and follow-ups were performed monthly. The primary endpoint was PFS, and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.Results: In total, 76 eligible patients were enrolled and randomly assigned (1:1 ratio). The IG group exhibited similar PFS compared to the CG group [median PFS: 3.88 (95% CI: 1.72-6.03) months vs. 3.98 (95% CI: 1.06-6.90) months, P=0.546] and OS [median OS: 9.00 (95% CI: 5.31-12.70) months vs. 9.40 (95% CI: 5.20-13.59) months, P=0.310]. ORR (21.1% vs. 18.4%, P=0.773) and DCR (60.5% vs. 60.5%, P=1.000) were of not statistically different between the IG and CG groups. As for safety, the IG group exhibited less frequent hypoproteinemia (31.6% vs. 55.3%, P=0.037) and lactate dehydrogenase increased (18.4% vs. 44.7%, P=0.014), while no differences in other adverse events were observed between the two groups.Conclusions: Intermittent dose apatinib plus docetaxel was equally effective and more tolerable than continuous dose apatinib plus docetaxel as a second-line therapy in patients with advanced GC/GEJAC.

show abstract

“…In addition to the above indicators, CBR was reported in a study of 19 patients with rmNPC conducted by Tao et al (52.6%) ( 16 ); 1-year survival rate was reported in a study of 21 patients with rmNPC conducted by Li et al (53.2%) ( 18 ) and in a study of 33 patients with rmNPC conducted by Ruan et al (81.8%) ( 15 ); and 2-year survival rate was reported in a study of 41 patients with rmNPC by Liya et al (41.5%) ( 14 ) and in a study of 33 patients with rmNPC by Ruan et al (21.2%) ( 15 ).…”

Section: Resultsmentioning

confidence: 94%

The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

Lin¹,

Weng

Wu³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Apatinib is a small-molecule tyrosine kinase inhibitor targeting VEGFR-2, which was recently used in a phase II clinical trial for the treatment of recurrent or metastatic nasopharyngeal carcinoma (rmNPC). However, there is no consistent conclusion on its efficacy and safety on rmNPC. This study conducted a meta-analysis of clinical research on the efficacy and safety of apatinib in the treatment of rmNPC.Methods: In April 2022, the PubMed, Web of Science, Scopus, Chinese National Knowledge Infrastructure (CNKI), CMB, and Wanfang databases were systematically searched, and relevant research literature were screened and analyzed. The clinical trial literatures using apatinib as the main single or combined treatment for rmNPC patients were selected and combined with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and other efficacy and safety indicators. Results:The meta-analysis included 12 studies, including 408 patients with rmNPC. The methodological index for nonrandomized studies scale was used to evaluate the bias of the included literatures and found that the bias was low. A total of 408 rmNPC patients were included in the included literature, with 11 studies being a phase II single-arm trial and one being a phase II non-randomized controlled trial. The ORR of patients with rmNPC treated with apatinib was 41.5% (95% CI: 34.8%, 48.2%), and the DCR was 80.2%

show abstract

<p>Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma</p>

Cited by 16 publications

References 18 publications

Apatinib in recurrent or metastatic head and neck cancer patients

Apatinib in recurrent or metastatic head and neck cancer patients

Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study

The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

Contact Info

Product

Resources

About